» Articles » PMID: 33231906

Nontoxic Cobalt(III) Schiff Base Complexes with Broad-Spectrum Antifungal Activity

Overview
Journal Chemistry
Specialty Chemistry
Date 2020 Nov 24
PMID 33231906
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to currently available antifungal drugs has quietly been on the rise but overshadowed by the alarming spread of antibacterial resistance. There is a striking lack of attention to the threat of drug-resistant fungal infections, with only a handful of new drugs currently in development. Given that metal complexes have proven to be useful new chemotypes in the fight against diseases such as cancer, malaria, and bacterial infections, it is reasonable to explore their possible utility in treating fungal infections. Herein we report a series of cobalt(III) Schiff base complexes with broad-spectrum antifungal activity. Some of these complexes show minimum inhibitory concentrations (MIC) in the low micro- to nanomolar range against a series of Candida and Cryptococcus yeasts. Additionally, we demonstrate that these compounds show no cytotoxicity against both bacterial and human cells. Finally, we report the first in vivo toxicity data on these compounds in Galleria mellonella, showing that doses as high as 266 mg kg are tolerated without adverse effects, paving the way for further in vivo studies of these complexes.

Citing Articles

Schiff Base-Based Molybdenum Complexes as Green Catalyst in the Epoxidation Reaction: A Minireview.

Mistri S, Mondal K Top Curr Chem (Cham). 2024; 382(4):35.

PMID: 39453566 DOI: 10.1007/s41061-024-00480-x.


Spectroscopic, anti-cancer, anti-bacterial and theoretical studies of new bivalent Schiff base complexes derived from 4-bromo-2,6-dichloroaniline.

Yousef T, Al-Janabi A Heliyon. 2024; 10(17):e37310.

PMID: 39319164 PMC: 11419873. DOI: 10.1016/j.heliyon.2024.e37310.


Photoredox cobalt-catalyzed regio-, diastereo- and enantioselective propargylation of aldehydes via propargyl radicals.

Wang L, Lin C, Chong Q, Zhang Z, Meng F Nat Commun. 2023; 14(1):4825.

PMID: 37563134 PMC: 10415309. DOI: 10.1038/s41467-023-40488-3.


DksA is a conserved master regulator of stress response in Acinetobacter baumannii.

Maharjan R, Sullivan G, Adams F, Shah B, Hawkey J, Delgado N Nucleic Acids Res. 2023; 51(12):6101-6119.

PMID: 37158230 PMC: 10325922. DOI: 10.1093/nar/gkad341.


Metals to combat antimicrobial resistance.

Frei A, Verderosa A, Elliott A, Zuegg J, Blaskovich M Nat Rev Chem. 2023; 7(3):202-224.

PMID: 37117903 PMC: 9907218. DOI: 10.1038/s41570-023-00463-4.


References
1.
Rubbiani R, Blacque O, Gasser G . Sedaxicenes: potential new antifungal ferrocene-based agents?. Dalton Trans. 2016; 45(15):6619-26. DOI: 10.1039/c5dt04231c. View

2.
Johnstone T, Suntharalingam K, Lippard S . The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev. 2016; 116(5):3436-86. PMC: 4792284. DOI: 10.1021/acs.chemrev.5b00597. View

3.
King A, Gellineau H, Ahn J, MacMillan S, Wilson J . Bis(thiosemicarbazone) Complexes of Cobalt(III). Synthesis, Characterization, and Anticancer Potential. Inorg Chem. 2017; 56(11):6609-6623. PMC: 8113979. DOI: 10.1021/acs.inorgchem.7b00710. View

4.
Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D . The antimalarial ferroquine: from bench to clinic. Parasite. 2011; 18(3):207-14. PMC: 3671469. DOI: 10.1051/parasite/2011183207. View

5.
Wheate N, Walker S, Craig G, Oun R . The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010; 39(35):8113-27. DOI: 10.1039/c0dt00292e. View